Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74. https://doi.org/10.1073/pnas.191367098.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, et al. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res. 2013;19(1):291–303. https://doi.org/10.1158/1078-0432.CCR-12-1611.

CAS  Article  PubMed  Google Scholar 

Jalalirad M, Haddad TC, Salisbury JL, Radisky D, Zhang M, Schroeder M, Tuma A, Leof E, Carter JM, Degnim AC, et al. Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance. Oncogene. 2021;40(14):2509–23. https://doi.org/10.1038/s41388-021-01711-x.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer. 2016;10:25–36. https://doi.org/10.4137/BCBCR.S32783.

CAS  Article  PubMed  PubMed Central  Google Scholar 

El Zein D, Hughes M, Kumar S, Peng X, Oyasiji T, Jabbour H, Khoury T. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17(5):382–91. https://doi.org/10.1016/j.clbc.2017.04.009.

Article  PubMed  PubMed Central  Google Scholar 

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, et al. Metaplastic breast cancers: genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast. 2019;44:29–32. https://doi.org/10.1016/j.breast.2018.12.010.

Article  PubMed  Google Scholar 

Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79:101888. https://doi.org/10.1016/j.ctrv.2019.08.004.

CAS  Article  PubMed  Google Scholar 

Sledge GW Jr. Curing metastatic breast cancer. J Oncol Pract. 2016;12(1):6–10. https://doi.org/10.1200/JOP.2015.008953.

Article  PubMed  Google Scholar 

Bertolin G, Tramier M. Insights into the non-mitotic functions of aurora kinase a: more than just cell division. Cell Mol Life Sci. 2020;77(6):1031–47. https://doi.org/10.1007/s00018-019-03310-2.

CAS  Article  PubMed  Google Scholar 

Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8(14):23937–54. https://doi.org/10.18632/oncotarget.14893.

Article  PubMed  PubMed Central  Google Scholar 

Tavernier N, Sicheri F, Pintard L. Aurora A kinase activation: different means to different ends. J Cell Biol. 2021;220(9):e202106128. https://doi.org/10.1083/jcb.202106128.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Cirak Y, Furuncuoglu Y, Yapicier O, Aksu A, Cubukcu E. Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis. J BUON. 2015;20(6):1414–9.

PubMed  Google Scholar 

Boos SL, Loevenich LP, Vosberg S, Engleitner T, Ollinger R, Kumbrink J, Rokavec M, Michl M, Greif PA, Jung A, et al. Disease modeling on tumor organoids implicates AURKA as a therapeutic target in liver metastatic colorectal cancer. Cell Mol Gastroenterol Hepatol. 2021;13(2):517–40. https://doi.org/10.1016/j.jcmgh.2021.10.008.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 expression is associated with decreased survival in breast cancer. Can Res. 2007;67(7):2932–7. https://doi.org/10.1158/0008-5472.CAN-06-4511.

CAS  Article  Google Scholar 

Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA. 1996;93(16):8379–83. https://doi.org/10.1073/pnas.93.16.8379.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, Morrione A, Giordano A, Cenciarelli C. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703. https://doi.org/10.1186/s12935-021-02396-8.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11(7):564–77. https://doi.org/10.1093/jmcb/mjz060.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, Shen J, Cai L, Cai X, Chen M. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021;14(1):157. https://doi.org/10.1186/s13045-021-01169-0.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ice RJ, McLaughlin SL, Livengood RH, Culp MV, Eddy ER, Ivanov AV, Pugacheva EN. NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors. Can Res. 2013;73(10):3168–80. https://doi.org/10.1158/0008-5472.CAN-12-4008.

CAS  Article  Google Scholar 

Miralaei N, Majd A, Ghaedi K, Peymani M, Safaei M. Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance. Cancer Med. 2021;10(18):6428–41. https://doi.org/10.1002/cam4.4161.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119(10):2304–12. https://doi.org/10.1002/ijc.22154.

CAS  Article  PubMed  Google Scholar 

Li Y, Tang K, Zhang H, Zhang Y, Zhou W, Chen X. Function of Aurora kinase A in taxol-resistant breast cancer and its correlation with P-gp. Mol Med Rep. 2011;4(4):739–46. https://doi.org/10.3892/mmr.2011.494.

CAS  Article  PubMed  Google Scholar 

Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, et al. Aurora-A kinase: a potent oncogene and target for cancer therapy. Med Res Rev. 2016;36(6):1036–79. https://doi.org/10.1002/med.21399.

Article  PubMed  Google Scholar 

Yang N, Wang C, Wang Z, Zona S, Lin SX, Wang X, Yan M, Zheng FM, Li SS, Xu B, et al. FOXM1 recruits nuclear aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Oncogene. 2017;36(24):3428–40. https://doi.org/10.1038/onc.2016.490.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Birbo B, Madu EE, Madu CO, Jain A, Lu Y. Role of HSP90 in cancer. Int J Mol Sci. 2021;22(19):10317. https://doi.org/10.3390/ijms221910317.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kim JY, Cho T-M, Park JM, Park S, Park M, Nam KD, Ko D, Seo J, Kim S, Jung E, et al. A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response. Oncogene. 2022. https://doi.org/10.1038/s41388-022-02269-y.

Article  PubMed  PubMed Central  Google Scholar 

Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 2011;9(5):577–88. https://doi.org/10.1158/1541-7786.MCR-10-0534.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Subramanian C, Grogan PT, Wang T, Bazzill J, Zuo A, White PT, Kalidindi A, Kuszynski D, Wang G, Blagg BSJ, et al. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition. Mol Oncol. 2020;14(9):2058–68. https://doi.org/10.1002/1878-0261.12686.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Sumi MP, Ghosh A. Hsp90 in human diseases: molecular mechanisms to therapeutic approaches. Cells. 2022;11(6):976. https://doi.org/10.3390/cells11060976.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Biebl MM, Buchner J. Structure, function, and regulation of the Hsp90 machinery. Cold Spring Harb Perspect Biol. 2019;11(9):106–17. https://doi.org/10.1101/cshperspect.a034017.

CAS  Article  Google Scholar 

Niu M, Zhang B, Li L, Su Z, Pu W, Zhao C, Wei L, Lian P, Lu R, Wang R, et al. Targeting HSP90 inhibits proliferation and induces apoptosis through AKT1/ERK pathway in lung cancer. Front Pharmacol. 2021;12:724192. https://doi.org/10.3389/fphar.2021.724192.

CAS  Article  PubMed  Google Scholar 

Dahiya V, Rutz DA, Moessmer P, Muhlhofer M, Lawatscheck J, Rief M, Buchner J. The switch from client holding to folding in the Hsp70/Hsp90 chaperone machineries is regulated by a direct interplay between co-chaperones. Mol Cell. 2022;82(8):1543-1556.e6. https://doi.org/10.1016/j.molcel.2022.01.016.

CAS  Article  PubMed  Google Scholar 

Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS ONE. 2011;6(3):e17649. https://doi.org/10.1371/journal.pone.0017649.

CAS 

留言 (0)

沒有登入
gif